Search
Akoustis Technologies Ord Shs
AKTSAdd to Watchlist
28.355USD
+1.345+4.98%
Market hours （ET）Quotes delayed by 15 min
1.51BMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
+4.98%
5 Days
+25.30%
1 Month
+39.41%
6 Months
0.00%
Year to Date
0.00%
1 Year
0.00%
Key Figures
27.210Open
28.450High
124.70KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
0.23%Turnover Ratio
27.010Prev. Close
26.160Low
2.43MTurnover
LossP/E Static
2.99P/B
0.00%Div Yield TTM
-167.18%ROA
29.16052wk High
0.52Volume Ratio
-167.95MNet Profit
53.40MShares
-1.3392EPS TTM
--Beta
-11970.59%ROE
14.72052wk Low
8.48%Amplitude
100.00%Gross Margin
1.51BMarket Cap
7.55Reward/Risk
4.34%Risk Rate
TradingKey Stock Score of Akoustis Technologies Ord Shs
Currency: USD Updated: 2026-06-23Key Insights
Akoustis Technologies Ord Shs's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 6 out of 12 in the Investment Holding Companies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Strong Buy, with the highest price target at 35.50.In the medium term, the stock price is expected to trend up.Despite a strong stock market performance and outperforming fundamentals over the past month, the technicals don't support the current trend.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Akoustis Technologies Ord Shs's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Positive+
Akoustis Technologies Ord Shs Highlights
StrengthsRisks
Aktis Oncology Inc is a United States-based biotechnology company. The Company focuses on developing targeted radiopharmaceuticals for treating solid tumor cancers. It also aims to deliver high doses of radiation directly to tumors, minimizing harm to healthy tissue. It transforms cancer care with novel platform technologies that enables to design and develop precision for radiopharmaceuticals. Its drugs are designed to bind to specific proteins on cancer cells, delivering radiation directly to the tumor.
Growing
The company is in a growing phase, with the latest annual income totaling USD 6.50M.
Undervalued
The company’s latest PE is -20.17, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 27.52M shares, increasing 3.93% quarter-over-quarter.
Held by Bill Nygren | OAKMX
Star Investor Bill Nygren | OAKMX holds 13.75K shares of this stock.
Analyst Rating
Based on
7
analysts
Strong Buy
Current Rating
35.500
Target Price
+43.20%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Akoustis Technologies Ord Shs News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Akoustis Technologies Ord Shs Info
Aktis Oncology Inc is a United States-based biotechnology company. The Company focuses on developing targeted radiopharmaceuticals for treating solid tumor cancers. It also aims to deliver high doses of radiation directly to tumors, minimizing harm to healthy tissue. It transforms cancer care with novel platform technologies that enables to design and develop precision for radiopharmaceuticals. Its drugs are designed to bind to specific proteins on cancer cells, delivering radiation directly to the tumor.
Ticker SymbolAKTS
CompanyAkoustis Technologies Ord Shs
CEORoden (Matthew)
Websitehttps://www.aktisoncology.com/
Related Instruments
-4.06%
0.00%
0.00%
0.00%
0.00%
-5.18%
0.00%
0.00%
+7.36%
0.00%
0.00%
+0.48%
0.00%
+0.40%
+19.67%
+22.21%
+1.13%
+0.10%
+2.25%Popular Instruments
70.729
-2.216 (-3.04%)
298.135
+3.835 (+1.30%)
200.646
+0.606 (+0.30%)
4018.310
-92.440 (-2.25%)
641.350
-29.400 (-4.38%)
1921.945
-41.655 (-2.12%)
1043.300
-8.470 (-0.81%)
349.805
+3.675 (+1.06%)
60277.090
-2163.610 (-3.46%)
381.150
-0.460 (-0.12%)
FAQs
What is the current price of Akoustis Technologies Ord Shs (AKTS)?
The current price of Akoustis Technologies Ord Shs (AKTS) is 27.01.
What is the symbol of Akoustis Technologies Ord Shs?
The ticker symbol of Akoustis Technologies Ord Shs is AKTS.
What is the 52-week high of Akoustis Technologies Ord Shs?
The 52-week high of Akoustis Technologies Ord Shs is 29.16.
What is the 52-week low of Akoustis Technologies Ord Shs?
The 52-week low of Akoustis Technologies Ord Shs is 14.72.
What is the market capitalization of Akoustis Technologies Ord Shs?
The market capitalization of Akoustis Technologies Ord Shs is 1.32B.
Is Akoustis Technologies Ord Shs (AKTS) currently rated as Buy, Hold, or Sell?
According to analysts, Akoustis Technologies Ord Shs (AKTS) has an overall rating of STRONG BUY, with a price target of 35.50.
What is the Earnings Per Share (EPS TTM) of Akoustis Technologies Ord Shs (AKTS)?
The Earnings Per Share (EPS TTM) of Akoustis Technologies Ord Shs (AKTS) is -1.26.
